ETX.L Regulatory News (ETX)

e-Therapeutics plc

Director/PDMR Shareholding - Amendment

This announcement replaces RNS Number : 7144Q released at 18:01 on 8th November 2012.

e-Therapeutics plc (AIM: ETX), the drug discovery and development company with a proprietary platform in network pharmacology, announced on 8th November 2012 that Professor Malcolm Young, CEO, had purchased 20,000 shares at 33.5 pence per share for his Self-Invested Personal Pension Fund.

Following this purchase, Professor Young's direct beneficial interest increased to 20,640,482 shares (of which 10,310,241 shares are held by Professor Young's wife), representing 14.9% of the total issued share capital of the Company. Professor Young also has an indirect interest, which remained unchanged at 403,148 shares, representing 0.29% of the Company's issued share capital. Professor Young's total interest is therefore 21,043,630 shares. The announcement made on 8 November erroneously stated this number as Professor Young's direct interest and that his indirect holding was additional.

-Ends-

For more information, please contact:

e-Therapeutics plc

Malcolm Young / Daniel Elger

Tel: +44 (0) 7909 915 068

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Fred Walsh / Hannah Woodley / Grishma Patel

Tel: +44 (0) 20 7886 2500

www.panmure.com

College Hill

Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@collegehill.com

CommStrat Group (US)

Ted Agne

Tel: (+1) 781 631 3117

Email: edagne@comstratgroup.com